Design of advanced siRNA therapeutics for the treatment of COVID-19

被引：18

作者：

Niktab, Iman ^{[1
,2
]}

Haghparast, Maryam ^{[1
]}

Beigi, Mohammad-Hossein ^{[1
,3
]}

Megraw, Timothy L. ^{[4
]}

Kiani, Amirkianoosh ^{[3
]}

Ghaedi, Kamran ^{[1
]}

机构：

[1] Univ Isfahan, Fac Biol Sci & Technol, Dept Cell & Mol Biol & Microbiol, Hezar Jerib Ave,Azadi Sq, Esfahan 8174673441, Iran

[2] Shahid Bahonar Univ Kerman, Dept Biol, Fac Sci, Kerman, Iran

[3] Ontario Tech Univ, Fac Engn & Appl Sci, Silicon Hall Micro Nano Mfg Facil, Oshawa, ON, Canada

[4] Florida State Univ, Coll Med, Dept Biomed Sci, West Call St, Tallahassee, FL 32306 USA

来源：

META GENE | 2021年 / 29卷

基金：

加拿大自然科学与工程研究理事会;

关键词：

siRNAs; COVID-19; SARS-CoV-2; qRT-PCR; SARS-COV; DISEASE; KNOCKING; PROGRESS;

D O I：

10.1016/j.mgene.2021.100910

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

COVID-19 is a newly emerged viral disease that is currently affecting the whole globe. A variety of therapeutic approaches are underway to block the SARS-CoV-2 virus. Among these methods, siRNAs could be a safe and specific option, as they have been tested against other viruses. siRNAs are a class of inhibitor RNAs that act promisingly as mRNA expression blockers and they can be designed to interfere with viral mRNA to block virus replication. In order to do this, we designed and evaluated the efficacy of six highly specific siRNAs, which target essential viral mRNAs with no predicted human genome off-targets. We observed a significant reduction in the copy number viral mRNAs after treatment with the siRNAs, and are expected to inhibit virus replication. We propose siRNAs as a potential co-therapy for acute SARS-CoV-2 infection.

引用

页数：4

共 19 条

[1] COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs [J].